Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target Aims: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic Australian cohort and evaluate the effectiveness of immunohistochemical screening. Methods and results: A retrospective cohort of 278 early stage lung adenocarcinomas and an additional 104 prospective non-small-cell lung cancer (NSCLC) cases referred for routine molecular testing were evaluated. ROS1 immunohistochemistry (IHC) was performed (D4D6 clone, Cell Signaling Technology) on all cases as well as fluorescence in-situ hybridization (FISH) using the ZytoVision and Abbott Molecular ROS1 FISH probes, with ≥15% of cells with split signals considered positive for rearrangement. Eightyeight cases (32%) from the retrospective cohort showed staining by ROS1 IHC, and one case (0.4%) showed ROS1 rearrangement by FISH. Nineteen of the prospective diagnostic cases showed ROS1 IHC staining, 12 (12%) cases of which were confirmed as ROS1 rearranged by FISH. There were no ROS1 rearranged cases that showed no expression of ROS1 with IHC. The ROS1 rearranged cases in the prospective cohort were all EGFR wild-type and anaplastic lymphoma kinase (ALK) rearrangement-negative. The sensitivity of ROS1 IHC in the retrospective cohort was 100% and specificity was 76%. 2017 , 70, 402-411. DOI: 10.1111 can be used to enrich for the likelihood of identifying a ROS1 rearranged lung cancer and prevent the need to undertake expensive and time-consuming FISH testing in all cases.
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target Aims: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic Australian cohort and evaluate the effectiveness of immunohistochemical screening. Methods and results: A retrospective cohort of 278 early stage lung adenocarcinomas and an additional 104 prospective non-small-cell lung cancer (NSCLC) cases referred for routine molecular testing were evaluated. ROS1 immunohistochemistry (IHC) was performed (D4D6 clone, Cell Signaling Technology) on all cases as well as fluorescence in-situ hybridization (FISH) using the ZytoVision and Abbott Molecular ROS1 FISH probes, with ≥15% of cells with split signals considered positive for rearrangement. Eightyeight cases (32%) from the retrospective cohort showed staining by ROS1 IHC, and one case (0.4%) showed ROS1 rearrangement by FISH. Nineteen of the prospective diagnostic cases showed ROS1 IHC staining, 12 (12%) cases of which were confirmed as ROS1 rearranged by FISH. There were no ROS1 rearranged cases that showed no expression of ROS1 with IHC. The ROS1 rearranged cases in the prospective cohort were all EGFR wild-type and anaplastic lymphoma kinase (ALK) rearrangement-negative. The sensitivity of ROS1 IHC in the retrospective cohort was 100% and specificity was 76%. Conclusions: ROS1 rearrangements are rare events in lung adenocarcinomas. Selection of cases for ROS1 FISH testing, by excluding EGFR/ALK-positive cases and use of IHC to screen for potentially positive cases,
Introduction
A new paradigm of targeted therapies has emerged for non-small-cell lung cancer (NSCLC) following the discovery of a number of targetable, generally mutually exclusive driver mutations such as those involving epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). Like ALK, rearrangements involving ROS1 are strongly predictive of response to the inhibitor crizotinib.
1
ROS1 is the oncogene product of the avian sarcoma RNA tumour virus [2] [3] [4] that encodes a transmembrane tyrosine kinase receptor from the insulin receptor subfamily, and has high homology with the intracellular kinase domain and ATP binding site of ALK. Activation of ROS1 leads to signalling through downstream oncogenic pathways, including phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3Ki-nase)/v-akt murine thymoma viral oncogene homolog 1 (Akt), mechanistic target of rapamycin (serine/threonine kinase) (MTOR) and RAS type GTPase family (RAS)-mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways. [5] [6] [7] Rearranged or activated ROS1 has been shown to have transforming potential in nude mice with NSCLC. 8 In addition, ROS1 gene rearrangements have been identified in other malignancies such as glioblastomas, 9 cholangiocarcinoma, [10] [11] [12] ovarian cancer, 13 gastric cancer 14 and colorectal cancer. 15 Driver mutations involving rearrangement of the ROS1 gene have been described recently in NSCLC and act as a target for tyrosine kinase inhibitors. ROS1 rearrangements have been identified in 1-3% of NSCLC, 8, 16, 17 but at higher rates in young, never-smoker, lung adenocarcinoma patients. 17 Due to the high homology between the kinase domains of ROS1 and ALK, ALK inhibitors were tested on ROS1-positive cell lines and tumours and were found to be inhibitory.
18
ROS1 rearranged tumours determined by break-apart fluorescence in-situ hybridization (FISH) testing were added to eligibility criteria for the PROFILE 1001 study, a Phase I study evaluating the ALK, MET protooncogene (MET)/ROS1 tyrosine kinase inhibitor crizotinib, which reported an overall objective response rate of 72% in 50 ROS1-positive patients. 19 Preliminary studies suggest that ROS1 rearranged patients treated with crizotinib may have a longer median response duration compared with ALK rearranged patients, due perhaps to crizotinib having a higher binding efficiency and potency to inhibit ROS1. 19 Although some ROS1 fusion partners are intrachromosomal involving the long (q) arm of chromosome 6, most partners occur on other chromosomes. 20 A total of 12 ROS1 fusion variants have been identified, with fusion partners that include solute carrier family 34 member 2 (SLC34-A2), CD74 molecule (CD74), tropomyosin 3 (TPM3), syndecan 4 (SDC4), ezrin (EZR), leucine rich repeats and immunoglobulin like domains 3 (LRIG3), golgi-associated PDZ and coiled-coil motif containing (GOPC), KDEL endoplasmic reticulum protein retention receptor 2 (KDELR2) and coiled-coil domain containing 6 (CCDC6). 8, 21, 22 Importantly, all fusions include the receptor tyrosine kinase domain of ROS1.
8
Although ROS1 rearranged lung cancers show promise as targetable tumours, there is a significant challenge in determining the best way to identify this rare alteration, often in small biopsy samples with limited tissue available for analysis. A number of studies show that ROS1 immunohistochemistry (IHC) can be utilized in conjunction with FISH to reveal ROS1 rearrangements in NSCLC. [23] [24] [25] [26] [27] [28] [29] [30] [31] The finding that some cases with ROS1 rearrangement show weak ROS1 immunoreactivity has led a number of authors to conclude that although diffuse-positive ROS1 IHC staining with moderate-strong intensity is associated more commonly with ROS1 rearrangement, this is not always the case. 23, 24, 26 Furthermore, strongly positive ROS1 IHC cases can sometimes be ROS1 FISH-negative. [23] [24] [25] 27, 28 IHC screening for ALK rearrangements in NSCLC has been established as an effective technique to identify ALK-positive tumours. [32] [33] [34] [35] [36] [37] An ALK IHC assay has also received FDA approval as a diagnostic companion test for screening for ALK rearrangements in the USA. We aimed to assess if a similar process of IHC screening could be useful to identify ROS1 rearrangements. In this study, we assessed the prevalence of ROS1 rearrangements in a retrospective cohort of Australian NSCLC comparing two techniques (IHC and FISH) and then applied the testing process in a prospective cohort of lung cancers referred for mutation assessment.
Materials and methods

P A T I E N T C O H O R T S
A retrospective cohort of 278 resected stages I-III lung adenocarcinomas from Royal Prince Alfred Hospital (RPAH) and Concord Repatriation General Hospital between January 1990 and May 2002 were included in the study, as described previously. [38] [39] [40] [41] [42] Formalin-fixed paraffin-embedded tissue was used to construct tissue microarrays to test for ROS1 expression and ROS1 gene rearrangement. EGFR, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and ALK status had been assessed in this cohort, as described previously. 16, 19 Ten per cent (29 of 278) harboured an activating EGFR mutation, 28% (77 of 278) harboured a KRAS mutation, 1% (three of 278) had an ALK rearrangement and 26% were not mutation tested (72 of 278) ( Table 1 ).
An additional cohort of 104 NSCLC cases referred for diagnostic molecular testing (EGFR, ALK or ROS1) , female never smoker). The cohort consisted of predominantly EGFR wild-type cases (66%); however, 15 cases (14%) possessed an EGFR mutation, five cases (5%) had a KRAS mutation, one case (1%) had a v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation and one case (1%) had a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (Table 1) . Eleven cases (11%) had unknown mutation status. These cases were referred for ROS1 rearrangement testing as requested by the clinical team or selected due to clinical features or ROS1 IHC positivity. Sixty-two cases were mutation tested at RPAH in parallel with diagnostic ROS1 testing (ROS1 IHC and FISH). Mutation testing was performed using Oncocarta version 1.0 and OncoFOCUS version 3 on the Sequenom MassARRAY platform (Sequenom/ Agena Bioscience, San Diego, CA, USA). The other 42 cases had previously undergone EGFR testing elsewhere. ALK rearrangement status was negative for all cases, except for two positive cases which were ALK FISH tested in parallel with ROS1 at the time due to clinician request. All cases in the diagnostic cohort were adenocarcinomas, except for three adenosquamous and three large-cell carcinomas.
R O S 1 I M M U N O H I S T O C H E M I S T R Y
IHC was performed on sections, cut at 4 lm, using the Cell Signaling Technology rabbit monoclonal ROS1 (D4D6) antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:50 dilution for 2 h. Staining was performed using the UltraView DAB universal detection kit (Roche, Basel, Switzerland) including an Amplification Kit (Roche), and was performed on a Benchmark ULTRA autostainer (Roche). Positive controls included lung tumour confirmed by FISH to be positive for ROS1 rearrangement. Any cytoplasmic staining for ROS1 IHC in tumour cells was considered positive. Non-specific staining of macrophages and type II pneumocytes was disregarded. The percentage of cells expressing ROS1 and intensity of expression was also evaluated, in addition to H-scores [% positive cells 9 intensity (1 mild, 2 moderate, 3 strong staining)].
R O S 1 F I S H
Interphase FISH was performed in a NATA (National Association of Testing Authorities)-accredited diagnostic laboratory for ROS1 rearrangement using the ZytoLight SPEC ROS1 Dual Colour Break Apart Probe (ZytoVision, Bremerhaven, Germany) and the LSI ROS1 (Tel) Spectrum Orange Probe and LSI ROS1 (Cen) Spectrum Green Probe (Abbott Molecular, Des Plaines, IL, USA). The ZytoVision FISH probe was used before the Abbott Molecular FISH probe was commercially available in March 2013. The retrospective cohort was analysed using the ZytoVision ROS1 FISH probe, and the prospective cohort utilized both FISH probes. In our experience both probes show equivalent performance, and both have been utilized and published in international cohorts. 23, 26, 27, [43] [44] [45] FISH was performed following the manufacturer's guidelines, except that Invitrogen (Carlsbad, CA, USA) pretreatment solution was used at 98-100°C for 20 min. Interphase signals were counted in at least 50 tumour nuclei per cases using an epifluorescence microscope (Zeiss, San Diego, CA, USA). Cases were classified as ROS1 FISH-positive if they showed ≥ 15% cells with split signals at least two signal distances apart or an isolated centromeric 3 0 (green signal) pattern (as indicated by the manufacturer and Mazieres et al. 45 ). The specific tissue region undergoing evaluation was verified by a pathologist and all FISH results were evaluated by a scientist and at least one expert pathologist with considerable experience reviewing lung cancer FISH (W.A.C. or S.O.T.).
Results
All cases within the retrospective cohort were evaluated using ROS1 IHC and FISH. Two of the 104 cases in the prospective diagnostic cohort were unable to have ROS1 IHC testing due to limited material available. Both cases were ROS1 FISH-negative.
Within the retrospective cohort a single case (0.4%) showed strong diffuse staining by ROS1 IHC, and this case was confirmed as rearrangement-positive by ROS1 FISH. This case was a poorly differentiated adenocarcinoma in a 66-year-old female, which showed a growth pattern containing intracytoplasmic mucin. All other cases were ROS1 rearrangementnegative by FISH. ROS1 IHC staining was present in 32% of cases (88 of 278); however, most of these cases showed weak immunoreactivity (1+).
Nineteen cases (Table 1) in the prospective cohort showed ROS1 IHC staining. Twelve cases (12%) were confirmed as ROS1 rearranged (Table 1) . These cases all showed 3+ immunoreactivity with H scores 270-300. The remaining seven IHC-positive cases were ROS1 FISH-negative. All these IHC-positive FISHnegative cases showed 3+ immunoreactivity except for one, which was 2+. H scores ranged from 40 to 300.
Four ROS1 rearranged cases showed a predominantly isolated 3 0 green locus (5 0 locus deletion) signal pattern (Table 2 ; one example is presented in Figure 1A ). A ROS1 IHC-positive case (adenosquamous carcinoma in a 56-year-old female, unknown smoking status, EGFR wild-type) that was confirmed rearranged with ROS1 FISH showed a signal pattern consisting predominantly of a single set of split signals per cell, with loss of the accompanying set of fusion signals (Table 2; Figure 1B ). The other ROS1 rearranged case showed a predominantly classical split signal pattern ( Table 2) .
One of the ROS1 IHC-positive FISH-negative cases (adenocarcinoma from a 62-year-old female, nonsmoker, EGFR wild-type) showed an atypical ROS1 FISH signal pattern of 26% isolated 5 0 (red) signals (Table 2; Figure 1C ). Additionally, another strongly ROS1 IHC-positive case (adenocarcinoma from a 62-year-old male, non-smoker, EGFR wild-type) was ROS1 FISH-negative (Table 2; Figure 1D ).
All ROS1-positive cases were adenocarcinomas, except for one adenosquamous carcinoma.
The sensitivity of ROS1 IHC in the retrospective cohort was 100% and specificity was 76%; positive predictive value (PPV) was 1% and negative predictive value (NPV) was 100%. If only 3+ IHC staining was classified as positive, the sensitivity and specificity of ROS1 IHC in the retrospective cohort was 100% with positive predictive value (PPV), and negative predictive value (NPV) also at 100%.
The combined 13 ROS1 rearranged cases were all EGFR wild-type (except for one case with unknown EGFR mutation status in the retrospective cohort) and were all ALK rearrangement-negative. Two cases were non-smokers and the remaining 10 cases had unknown smoking history.
Discussion
Compared with rearrangements involving ALK, which are reported to occur in approximately 3% of patients with NSCLC, 46 ROS1 rearrangements have been reported to occur at slightly lower percentages (1%). 46, 47 This was somewhat validated in our retrospective cohort, which showed 0.4% of 278 cases with ROS1 rearrangement. As the prospective cohort of 104 cases was enriched with patients who were confirmed previously to be EGFR and ALK wild-type, the rate of ROS1 rearrangements was higher (12%). Despite the lower rate of ROS1 rearrangement, compared with that of ALK the rate of response to targeted therapy appears slightly higher with a longer median duration of response and progression-free survival, 19 adding a valuable incentive to screen for ROS1 rearrangements.
Due presumably to the high sensitivity of ROS1 IHC, our retrospective and prospective cohorts showed a notable level of ROS1 immunoreactivity in cases that were negative for a ROS1 rearrangement by FISH. Although, theoretically, break-apart FISH can detect all rearrangements involving the common break-point region, it has been suggested that it may be difficult to identify ROS1 fusions involving intrachromosomal rearrangements on the same chromosome, such as EZR-ROS1 by break-apart FISH 16 due to close location of the split signals. ROS1 rearrangements involving GOPC (known formally as FIG) would not be detected by some break-apart FISH assays, as the 5 0 probe overlaps or includes GOPC, which is only 134 kb upstream. 13, 17 The ZytoVision ROS1 FISH probe is able to detect GOPC-ROS1 fusions; however, as the Abbott Molecular ROS1 FISH probe is designed with the 5 0 telomeric probe covering both ROS1 and GOPC genes, it is thought that the FISH probe cannot detect GOPC-ROS1 fusions. Fusions with GOPC, however, are thought to make up only 3% of ROS1 fusion partners in NSCLC, 47 although further data are required to characterize the frequency of this fusion partner with certainty.
High ROS1 IHC expression without ROS1 FISH positivity may be caused by a number of factors. A fusion gene not revealed by FISH, such as a GOPC-ROS1 fusion, could be responsible for a subset of these cases; however, the ZytoVision FISH probe, which can detect this fusion, was used to confirm FISH results in all but three of these cases, where further tissue was not available for assessment. Alternative cryptic ROS1 rearrangements could also explain why some cases show high protein ROS1 expression with no detected ROS1 rearrangement by FISH. Alternative methods such as reverse transcription-polymerase chain reaction (RT-PCR) and sequencing 20, 26, 31, 43 have revealed ROS1 rearrangements in similar cases, and would be of great benefit when feasible diagnostically. In addition, activation of 
A-i
A-ii A-iii the ROS1 oncogene could take place independently of structural DNA aberrations at the ROS1 locus and be epigenetically driven, such as by alternative transcript initiation -which has been documented for ALK.
48
Other mechanisms of RNA and protein conformational activation of ROS1 could also contribute theoretically, but so far have not yet manifested in studies.
During the early stage of this study, limited commercial options for ROS1 FISH probes were available, therefore we utilized the ZytoVision ROS1 break-apart FISH probe before the Abbott Molecular ROS1 FISH probe was also available. Many studies have used either the Abbott Molecular ROS1 FISH probe set or the ZytoVision probe set, 23, 26, 27, 43, 44 including the EUROS1 cohort conducted in six European countries. 45 Interestingly, Warth et al. 23 described that ROS1 IHC positivity, but not ROS1 rearrangement, in 1478 cases was associated with prolonged overall survival. This suggests that ROS1 immunoreactivity may have more clinical significance than understood previously; however, its association with response to ROS1 inhibitors has not been investigated.
No false negative ROS1 IHC cases were observed in the retrospective cohort. The only ROS1 rearranged case in the retrospective cohort expressed ROS1 with 3+ intensity IHC, and similarly in the prospective cohort all ROS1 rearranged cases expressed ROS1 with 3+ IHC intensity.
In our study, ROS1 IHC identified all ROS1 rearranged tumours, as all ROS1 FISH-positive cases in our cohorts were immunoreactive. Our data suggest that IHC for ROS1 is a highly sensitive, but not as specific, method to screen for ROS1 rearrangements with a very high negative predictive value. As such, we recommend IHC screening, followed by FISH confirmation. While our results suggest that FISH could be undertaken only on those cases with diffuse strong intensity IHC staining (3+ staining in at least 90% of tumour cells, H score ≥270), assessment of intensity is subjective and other studies have shown that occasional FISH+ cases may be missed with such an approach, 24, 26 so in our centre we have adopted an approach of FISH testing cases with any ROS1 IHC positivity. A similar approach has been shown to be effective in identifying ALK rearranged lung cancer. 32 Compared with performing FISH as a routine screening method for ROS1 rearrangements in all EGFR/ALK-negative NSCLC cases, ROS1 IHC is preferable due to the reduced cost and reduced labour involved in interpretation. Confirmatory FISH could be reserved for cases showing diffuse and moderately strong ROS1 IHC staining in centres where FISH testing is not readily available.
In conclusion, potentially targetable ROS1 gene rearrangements occur in a very small percentage of lung adenocarcinomas and are largely mutually exclusive with EGFR mutations and ALK rearrangements. Screening with IHC is highly sensitive, but not as specific, and may be a suitable method of reducing the number of cases requiring FISH to identify the ROS1 genetic abnormality. Selection of cases for ROS1 FISH testing such as exclusion of EGFR/ALK-positive cases and the use of ROS1 IHC to screen for potentially positive cases can be used to enrich for the likelihood of identifying a ROS1 rearranged lung cancer and prevent the need to undertake expensive and time-consuming FISH testing in all cases.
